Rock Springs Capital Management LP Purchases 1,349,145 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Rock Springs Capital Management LP raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 107.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,599,425 shares of the biopharmaceutical company's stock after purchasing an additional 1,349,145 shares during the quarter. Rock Springs Capital Management LP owned 0.87% of Amicus Therapeutics worth $24,487,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of FOLD. Covestor Ltd raised its holdings in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. R Squared Ltd purchased a new position in shares of Amicus Therapeutics in the fourth quarter worth $79,000. KBC Group NV lifted its holdings in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Sciencast Management LP purchased a new stake in shares of Amicus Therapeutics during the fourth quarter valued at $100,000. Finally, Stephens Inc. AR bought a new stake in Amicus Therapeutics in the 4th quarter worth about $101,000.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded up $0.15 during trading hours on Friday, reaching $7.35. 3,683,896 shares of the company traded hands, compared to its average volume of 2,619,132. The firm has a 50-day moving average price of $8.16 and a 200 day moving average price of $9.40. The company has a market cap of $2.26 billion, a P/E ratio of -40.83, a P/E/G ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 12-month low of $6.20 and a 12-month high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FOLD. Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.